Keloid Market Epidemiology Report 2025-2035 | Drug Pipeline, Therapies, and Regional Outlook

According to the IMARC Group, the keloid market size reached a value of USD 242.8 million in 2024. Looking forward, the 7MM is expected to reach USD 356.3 million by 2035, exhibiting a compound annual growth rate (CAGR) of 3.53% during 2025-2035. This can be attributed to the growing acceptance of radiofrequency ablation, which offers several advantages over traditional surgical excision, such as fewer complications, improved function, and less scarring.

Keloid is a medical condition that occurs when an excess amount of collagen, a protein that develops the connective tissue in the skin, is produced during the healing process of a wound or injury. The keloid market is experiencing substantial growth, driven by several critical factors. Primarily, the rising incidence of skin injuries and surgical procedures is significantly increasing the demand for effective keloid treatments. Moreover, advancements in dermatological medications, including laser therapy and corticosteroid injections, are enhancing therapeutic outcomes, thereby propelling market expansion.

Additionally, growing awareness among patients and healthcare providers about the availability and efficacy of keloid treatments is leading to earlier intervention and better management of the condition. Furthermore, the keloid market is benefiting from increased research and development (R&D) activities aimed at discovering new therapeutic approaches, such as cryotherapy and radiation therapy, which are proving to be effective in managing keloid scars. The rising popularity of non-invasive and minimally invasive treatment options is also contributing to market expansion as patients seek medications with fewer side effects and quicker recovery times. In addition, collaborations between pharmaceutical companies and research institutions are fostering the development of new drugs and therapeutic modalities. The integration of advanced technologies, such as fractional lasers and intralesional therapies, is anticipated to drive the growth of the keloid market in the coming years.

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario 

• Historical, current, and future performance of the keloid market

• Historical, current, and future performance of various therapeutic categories in the market 

• Sales of various drugs across the keloid market

• Reimbursement scenario in the market 

• In-market and pipeline drugs

Request for a sample of this report: https://www.imarcgroup.com/keloid-market/requestsample

This report also provides a detailed analysis of the current keloid market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview 

• Mechanism of Action 

• Regulatory Status 

• Clinical Trial Results 

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview 

• Mechanism of action 

• Regulatory status 

• Clinical trial results 

• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the keloid market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these Key Players:

1. Bristol-Myers Squibb
2. Sandoz
3. 3M Health Care
4. Teva Pharmaceuticals
5. UCB
6. UroGen Pharma
7. Amneal Biosciences
8. Allergan
9. Kissei Pharmaceuticals
10. Topadur Pharma
11. Innovo Therapeutics
12. AiViva BioPharma
13. Sirnaomics

Countries Covered:

• United States 

• Germany 

• France 

• United Kingdom 

• Italy 

• Spain 

• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145